{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T22:27:44Z","timestamp":1778711264421,"version":"3.51.4"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,1,4]],"date-time":"2020-01-04T00:00:00Z","timestamp":1578096000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,4]],"date-time":"2020-01-04T00:00:00Z","timestamp":1578096000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s11239-019-02018-1","type":"journal-article","created":{"date-parts":[[2020,1,4]],"date-time":"2020-01-04T08:02:36Z","timestamp":1578124956000},"page":"431-440","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Vonicog alfa for the management of von Willebrand disease: a comprehensive review and single-center experience"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6001-252X","authenticated-orcid":false,"given":"Thuy","family":"Tran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Arnall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald C.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie","family":"Ward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surabhi","family":"Palkimas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Man","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,4]]},"reference":[{"issue":"4","key":"2018_CR1","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1182\/blood.V70.4.895.895","volume":"70","author":"ZM Ruggeri","year":"1987","unstructured":"Ruggeri ZM, Zimmerman TS (1987) Von Willebrand factor and von Willebrand Disease. Blood 70(4):895\u2013904","journal-title":"Blood"},{"issue":"2","key":"2018_CR2","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1182\/blood.V69.2.454.454","volume":"69","author":"F Rodeghiero","year":"1987","unstructured":"Rodeghiero F, Castaman G, Dini E (1987) Epidemiological investigation of the prevalence of von Willebrand\u2019s disease. Blood 69(2):454\u2013459","journal-title":"Blood"},{"issue":"5","key":"2018_CR3","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/GIM.0b013e3182035931","volume":"13","author":"PD James","year":"2011","unstructured":"James PD, Goodeve AC (2011) Von Willebrand disease. Genet Med 13(5):365","journal-title":"Genet Med"},{"issue":"12","key":"2018_CR4","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1358\/dot.2016.52.12.2570978","volume":"52","author":"M Singal","year":"2016","unstructured":"Singal M, Kouides PA (2016) Recombinant von Willebrand factor: a first-of-its-kind product for von Willebrand disease. Drugs Today (Barc) 52(12):653\u2013664","journal-title":"Drugs Today (Barc)"},{"issue":"5","key":"2018_CR5","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1182\/blood-2013-01-479527","volume":"122","author":"PM Mannucci","year":"2013","unstructured":"Mannucci PM, Kepmton C, Millar C, Romond E, Shapiro A, Birschmann I et al (2013) Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial. Blood 122(5):648\u2013657","journal-title":"Blood"},{"issue":"1","key":"2018_CR6","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/jth.14313","volume":"17","author":"F Peyvandi","year":"2019","unstructured":"Peyvandi F, Mamaev A, Wang JD, Stasyshyn O, Timofeeva M, Curry N et al (2019) Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery. J Thromb Haemost 17(1):52\u201362","journal-title":"J Thromb Haemost"},{"issue":"17","key":"2018_CR7","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1182\/blood-2015-02-629873","volume":"126","author":"JC Gill","year":"2015","unstructured":"Gill JC, Castaman G, Windyga J, Kouides P, Ragni M, Leebeek FW et al (2015) Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease. Blood 126(17):2038\u20132046","journal-title":"Blood"},{"issue":"3","key":"2018_CR8","doi-asserted-by":"publisher","first-page":"e120","DOI":"10.1111\/hae.13436","volume":"24","author":"AC Weyand","year":"2018","unstructured":"Weyand AC, Jesudas R, Pipe SW (2018) Advantage of recombinant von Willebrand factor for peri-operative management in paediatric acquired von Willebrand syndrome. Haemophilia 24(3):e120\u2013e121","journal-title":"Haemophilia"},{"issue":"4","key":"2018_CR9","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1097\/MBC.0000000000000807","volume":"30","author":"M Rajpurkar","year":"2019","unstructured":"Rajpurkar M, Frey MJ, Sabo C, Hollon W (2019) Recombinant\u00a0Von Willebrand factor\u00a0concentrate in 2A\u00a0Von\u00a0Willebrand\u00a0disease: comparison to plasma-derived\u00a0Von Willebrand factor\u00a0concentrate therapy. Blood Coagul Fibrinol 30(4):168\u2013170","journal-title":"Blood Coagul Fibrinol"},{"issue":"8943","key":"2018_CR10","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S0140-6736(95)90166-3","volume":"345","author":"T Koster","year":"1995","unstructured":"Koster T, Blann AD, Bri\u00ebt E, Vandenbroucke JP, Rosendaal FR (1995) Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345(8943):152\u2013155","journal-title":"Lancet"},{"issue":"3","key":"2018_CR11","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.1111\/j.1365-2516.2012.02758.x","volume":"18","author":"A Coppola","year":"2012","unstructured":"Coppola A, Franchini M, Makris M, Santagostino E, Di Minno G, Mannucci PM (2012) Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies. Haemophilia 18(3):e173\u2013e178","journal-title":"Haemophilia"},{"issue":"8","key":"2018_CR12","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1111\/jth.14472","volume":"17","author":"W Miesbach","year":"2019","unstructured":"Miesbach W (2019) Phase 3 study\u00a0of\u00a0recombinant\u00a0von Willebrand factor\u00a0in\u00a0patients\u00a0with\u00a0severe\u00a0von Willebrand disease\u00a0who\u00a0are\u00a0undergoing\u00a0elective surgery:\u00a0comment. J Thromb Haemost 17(8):1403\u20131405","journal-title":"J Thromb Haemost"},{"key":"2018_CR13","unstructured":"Baxalta US Inc. Vonvendi (von Willebrand factor [recombinant]) package insert. Lexington, MA; Feb 2019"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-019-02018-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-019-02018-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-019-02018-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T00:28:58Z","timestamp":1609633738000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-019-02018-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,4]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["2018"],"URL":"https:\/\/doi.org\/10.1007\/s11239-019-02018-1","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,4]]},"assertion":[{"value":"4 January 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}